46 results on '"Supiot, Stephane"'
Search Results
2. LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY
3. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
4. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies
5. Dosimetric feasibility of dose-painting radiotherapy for targeting hypoxia in prostate cancer on a novel ring gantry radiotherapy system.
6. Supplementary Fig. S1 from Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
7. Supplementary Fig. S1 from Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
8. Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.
9. Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial).
10. Salvage radiotherapy guided by functional imaging for macroscopic local recurrence following radical prostatectomy: A multicentric retrospective study.
11. Salvage radiotherapy guided by functional imaging for macroscopic local recurrence following radical prostatectomy: A multicentric retrospective study.
12. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
13. Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey
14. Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population
15. Ensemble Learning for Prediction of Toxicity in Prostate Cancer Radiotherapy: Comparison Between Stacking and Genetic Algorithm Weighted Voting
16. Local dose analysis to predict acute and late urinary toxicities after prostate cancer radiotherapy: Assessment of cohort and method effects
17. Haute Couture or Ready-To-Wear? Tailored Pelvic Radiotherapy for Prostate Cancer Based on Individualized Sentinel Lymph Node Detection
18. Oligopelvis-GETUG P07: A multicenter phase II trial of combined salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses of prostate cancer.
19. Late toxicity and quality of life from GETUG-AFU 22 study.
20. Comparison of Machine Learning Algorithms and Oversampling Techniques for Urinary Toxicity Prediction After Prostate Cancer Radiotherapy
21. Healthcare system barriers of breast and thyroid screening for childhood and young adulthood cancer survivors in France A qualitative study of the DeNaCaPST programme at one year
22. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475).
23. Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?
24. Daily versus weekly prostate cancer image-guided radiotherapy: A phase 3, multicenter, randomized trial.
25. SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.
26. Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910–7
27. Moderately hypofractionated prostate external-beam radiotherapy: an emerging standard
28. Editorial: Controversies and Perspectives in the Use of Postoperative Radiotherapy for Prostate Cancer
29. Abstract A28: Mutational landscape of TP53 in localized prostate cancer
30. Treatment of cutaneous and/or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (cGVHD) by a total nodal irradiation (TNI)
31. The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy.
32. Combined abiraterone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.
33. Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer
34. OLIGOPELVIS – GETUG P07, a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer: Preplanned analysis of acute toxicity.
35. OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer
36. Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475.
37. REBECA: A phase I study of bevacizumab (BEV) and whole-brain radiation therapy (WBRT) for treatment of solid tumors brain metastases (BM), EudraCT: 2009-015977-11.
38. Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: A feasibility study
39. Ameloblastic Fibrosarcoma of the Mandible
40. Prospective determination of long-term toxicity and quality of life (QoL) of patients with prostate cancer after intensity-modulated radiotherapy (IMRT).
41. Pharmacotherapeutic Management of Locally Advanced Prostate Cancer
42. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
43. A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies
44. Using Simulated Interviews to Teach Junior Medical Students to Disclose the Diagnosis of Cancer
45. Mechanisms of Cell Sensitization to α Radioimmunotherapy by Doxorubicin or Paclitaxel in Multiple Myeloma Cell Lines
46. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.